Q-omics provides the consensus-scored CUL5 profile across patient tissues and cancer cell-line models. CUL5 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CUL5 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, CUL5 RNA expression shows 21,299 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where CUL5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CUL5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CUL5 survival associations across molecular data types. CUL5 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CUL5 RNA expression–survival associations across cancer types. High CUL5 expression shows unfavorable associations in CESC, UVM, ACC and LIHC, but favorable associations in KIRC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CUL5 RNA expression.
This table summarizes CUL5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for CUL5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CUL5 shows lower tumor expression in THCA, KIRC and KIRP and higher tumor expression in LIHC, CHOL and HNSC. The THCA box plot shows higher CUL5 RNA expression in normal versus tumor tissue (log2 FC = −0.811, t-test p < 0.001).
This table shows molecular features associated with CUL5 in patient tissues and cancer cell lines. In patient samples, CUL5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CUL5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
